BIOTON S.A. (BIO.WA)
PLN 2.98
(-0.83%)
PLN 2.98
(-0.83%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | 0.03 PLN | 59.64% |
| 2022 | 0.02 PLN | -50.6% |
| 2021 | 0.03 PLN | -91.6% |
| 2020 | 0.40 PLN | 127.03% |
| 2019 | -1.48 PLN | -577.42% |
| 2018 | 0.31 PLN | 466.43% |
| 2017 | -0.08 PLN | 74.36% |
| 2016 | -0.33 PLN | 94.58% |
| 2015 | -6.09 PLN | -15325.0% |
| 2014 | 0.04 PLN | 152.49% |
| 2013 | -0.08 PLN | -114.38% |
| 2012 | 0.53 PLN | 135.57% |
| 2011 | -1.49 PLN | -167.73% |
| 2010 | 2.20 PLN | 115.69% |
| 2009 | -14.02 PLN | -91.27% |
| 2008 | -7.33 PLN | -804.81% |
| 2007 | 1.04 PLN | -72.27% |
| 2006 | 3.75 PLN | 143.51% |
| 2005 | 1.54 PLN | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q2 | -0.03 PLN | 44.63% |
| 2024 Q1 | -0.06 PLN | -193.32% |
| 2023 Q3 | -0.05 PLN | -409.64% |
| 2023 Q2 | 0.02 PLN | 1137.5% |
| 2023 Q1 | -0.00 PLN | -102.74% |
| 2023 FY | - PLN | 59.64% |
| 2023 Q4 | 0.06 PLN | 222.37% |
| 2022 Q2 | 0.02 PLN | 146.85% |
| 2022 Q3 | -0.02 PLN | -231.58% |
| 2022 Q4 | 0.06 PLN | 360.0% |
| 2022 FY | - PLN | -50.6% |
| 2022 Q1 | -0.04 PLN | -860.53% |
| 2021 FY | - PLN | -91.6% |
| 2021 Q1 | -0.06 PLN | -126.82% |
| 2021 Q4 | -0.00 PLN | -107.08% |
| 2021 Q2 | 0.04 PLN | 172.37% |
| 2021 Q3 | 0.05 PLN | 25.76% |
| 2020 Q4 | 0.22 PLN | 688.53% |
| 2020 FY | - PLN | 127.03% |
| 2020 Q1 | 0.07 PLN | 115.15% |
| 2020 Q2 | 0.08 PLN | 14.06% |
| 2020 Q3 | 0.03 PLN | -64.91% |
| 2019 Q1 | 0.31 PLN | 167.39% |
| 2019 Q2 | -1.02 PLN | -429.03% |
| 2019 Q3 | -0.09 PLN | 91.62% |
| 2019 Q4 | -0.46 PLN | -438.01% |
| 2019 FY | - PLN | -577.42% |
| 2018 Q3 | -0.03 PLN | -103.48% |
| 2018 Q1 | 0.03 PLN | -59.65% |
| 2018 FY | - PLN | 466.43% |
| 2018 Q2 | 0.77 PLN | 2919.61% |
| 2018 Q4 | -0.46 PLN | -1616.42% |
| 2017 Q4 | 0.06 PLN | 469.59% |
| 2017 FY | - PLN | 74.36% |
| 2017 Q3 | -0.02 PLN | -228.85% |
| 2017 Q2 | -0.01 PLN | 96.0% |
| 2017 Q1 | -0.13 PLN | 50.0% |
| 2016 Q4 | -0.26 PLN | -680.78% |
| 2016 FY | - PLN | 94.58% |
| 2016 Q1 | 0.01 PLN | 100.24% |
| 2016 Q2 | -0.05 PLN | -438.78% |
| 2016 Q3 | -0.03 PLN | 33.13% |
| 2015 FY | - PLN | -15325.0% |
| 2015 Q4 | -6.19 PLN | -6755.91% |
| 2015 Q3 | 0.09 PLN | 923.01% |
| 2015 Q2 | -0.01 PLN | -154.33% |
| 2015 Q1 | 0.02 PLN | 197.14% |
| 2014 FY | - PLN | 152.49% |
| 2014 Q3 | 0.03 PLN | -61.35% |
| 2014 Q2 | 0.07 PLN | 216.16% |
| 2014 Q4 | 0.01 PLN | -73.48% |
| 2014 Q1 | -0.06 PLN | 12.11% |
| 2013 FY | - PLN | -114.38% |
| 2013 Q4 | -0.07 PLN | -312.96% |
| 2013 Q2 | 0.01 PLN | 304.48% |
| 2013 Q1 | -0.01 PLN | 96.81% |
| 2013 Q3 | -0.02 PLN | -218.25% |
| 2012 Q2 | 0.20 PLN | -74.36% |
| 2012 Q1 | 0.78 PLN | 173.58% |
| 2012 FY | - PLN | 135.57% |
| 2012 Q3 | -0.18 PLN | -190.0% |
| 2012 Q4 | -0.21 PLN | -16.67% |
| 2011 Q3 | 0.20 PLN | 157.14% |
| 2011 FY | - PLN | -167.73% |
| 2011 Q1 | -0.32 PLN | -117.2% |
| 2011 Q2 | -0.35 PLN | -9.37% |
| 2011 Q4 | -1.06 PLN | -630.0% |
| 2010 Q1 | -0.43 PLN | 96.25% |
| 2010 Q3 | -0.20 PLN | -123.81% |
| 2010 FY | - PLN | 115.69% |
| 2010 Q4 | 1.86 PLN | 1030.0% |
| 2010 Q2 | 0.84 PLN | 295.35% |
| 2009 Q3 | -0.29 PLN | 66.67% |
| 2009 Q4 | -11.48 PLN | -3858.62% |
| 2009 Q2 | -0.87 PLN | -26.09% |
| 2009 Q1 | -0.69 PLN | 0.0% |
| 2009 FY | - PLN | -91.27% |
| 2008 FY | - PLN | -804.81% |
| 2007 FY | - PLN | -72.27% |
| 2006 FY | - PLN | 143.51% |
| 2005 FY | - PLN | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| Bioceltix S.A. | -3.49 PLN | 100.759% |
| Captor Therapeutics Spolka Akcyjna | -15.19 PLN | 100.174% |
| Mabion S.A. | 2.55 PLN | 98.961% |
| Molecure S.A. | -1.09 PLN | 102.431% |
| NanoGroup S.A. | -0.39 PLN | 106.795% |
| Pharmena S.A. | 2.60 PLN | 98.981% |
| Poltreg S.A. | -2.91 PLN | 100.911% |
| Pure Biologics Spólka Akcyjna | -11.19 PLN | 100.237% |
| Ryvu Therapeutics S.A. | -4.02 PLN | 100.659% |
| Synthaverse S.A. | 0.07 PLN | 60.857% |
| Urteste S.A. | -4.32 PLN | 100.613% |